The injectable hydrogel loaded with doxorubicin (DOX) and lysed OK-432 (lyOK-432) promotes an antitumor immunity through activating the STING pathway, conferring effective therapy for residual hepatocellular carcinoma (HCC) after incomplete radiofrequency ablation (102). Here, STING1 is linked to hepatocellular carcinoma.